Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE: UFOX + Cetuximab vs FOLFOX-4 + Cetuximab in mCRC
NCT00439517Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of tegafur + uracil in colorectal cancer (metastatic) (mCRC), sponsored by Merck KGaA. Started Feb 2007; status: completed.
02
Drugs
tegafur + uracil
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00439517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439517.